|
|
Vaccine Detail
|
Anti-PRAME Immunotherapeutic GSK2302032A Vaccine |
| Vaccine Information |
- Vaccine Name: Anti-PRAME Immunotherapeutic GSK2302032A Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007269
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- PRAME
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: The treatment consists of recombinant PRAME protein administered with a fixed dose of the proprietary immunostimulant AS15 (referred to as the PRAME immunotherapeutic) (Pujol et al., 2016).
- Description: An immunotherapeutic agent targeting the tumor-associated antigen (TAA), preferentially expressed antigen of melanoma (PRAME), with potential antineoplastic activity. (NCIT_C116848).
This vaccine has been used in Non-Small Cell Lung Cancer clinical trials. NCT01853878
|
| Host Response |
|
|
| References |
NCIT_C116848: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116848]
Pujol et al., 2016: Pujol JL, De Pas T, Rittmeyer A, Vallières E, Kubisa B, Levchenko E, Wiesemann S, Masters GA, Shen R, Tjulandin SA, Hofmann HS, Vanhoutte N, Salaun B, Debois M, Jarnjak S, De Sousa Alves PM, Louahed J, Brichard VG, Lehmann FF. Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016; 11(12); 2208-2217. [PubMed: 27544054].
|
|
